NCT04012944进行中（未招募）不适用
A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients (SIRONA 2 Trial)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 81
- 试验地点
- 9
- 主要终点
- Safety: Freedom from Adverse Events
研究概览
简要总结
This is a prospective, multi-center, open-label, single-arm CE-Mark trial to assess device safety and efficacy of the Cordella PA Sensor System in up to 75 New York Heart Association (NYHA) Class III Heart Failure patients who will receive the Cordella PA Sensor Implant.
详细描述
The study objectives are:
- To establish that the Cordella PA Sensor can be safely delivered, deployed, and remain stable within the target pulmonary artery (PA) segment through 30 days post-implant.
- To compare Cordella PA Sensor System pressure measurements with fluid-filled catheter PA pressure measurements obtained by standard right heart catheterization (RHC) at 90 days post implant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has given written informed consent
- •Male or female, at least 18 years of age
- •Diagnosis of HF ≥ 6 months with either preserved or reduced left ventricular ejection fraction (LVEF) and NYHA Class III HF at the time of Screening
- •HF related hospitalization, HF treatment in a hospital day-care setting, or unplanned outpatient clinic HF visit within 12 months prior to consent and/or increase of N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) (or Brain Natriuretic Peptide (BNP)) at time of Screening defined as:
- •Subjects with LVEF ≤ 40%: NT-proBNP ≥ 1000 pg/mL (or BNP ≥ 250 pg/mL).
- •Subjects with LVEF > 40%: NT-proBNP ≥ 700 pg/mL (or BNP ≥ 175 pg/mL). Thresholds for NT-proBNP and BNP (for both LVEF ≤ 40% and LVEF > 40%) will be corrected for body mass index (BMI) using a 4% reduction per BMI unit over 25 kg/m2
- •Subjects must be receiving appropriate medical management of HF for 3 months prior to Screening and clinically stable for at least 1 month prior to study entry
- •Subjects who are physically able to hold the myCordella™ Patient Reader unit (approximate weight 600g) against the ventral thoracic surface for up to 2 minutes per day while in a seated position, as well as dock and undock the myCordella™ Patient Reader
- •Subjects with sufficient eyesight, hearing, and mental capacity to respond to the myCordella™ Patient Reader's audio/visual cues and operate the myCordella™ Patient Reader
- •Subject has sufficient Cellular and/or Wi- Fi Internet coverage at home
- •Subject agrees to return to the treating Investigator for all scheduled follow up visits and can return to the hospital for follow up
排除标准
- •Subjects with primary pulmonary hypertension
- •Subjects with an active infection at the Cordella PA Sensor Implant Visit
- •Subjects with history of pulmonary embolism or deep vein thrombosis
- •Subjects who have had a major cardiovascular event (e.g., myocardial infarction, stroke) within 2 months of the Screening Visit
- •Subjects whereby RHC is contraindicated
- •Implanted with a Cardiac Rhythm Management (CRM) Device (Internal Cardiac Defibrillator (ICD) or pacemaker) or Cardiac Resynchronization Therapy (CRT)-Pacemaker (CRT-P) or CRT-Defibrillator (CRT-D) less than 90 days prior to screening visit
- •Any major surgery within 30 days of the Sensor Implant Visit.
- •Subjects with a Glomerular Filtration Rate (GFR) <25 ml/min or who are on chronic renal dialysis
- •Specific liver enzymes [Aspartate Aminotransferase (AST) (SGOT), and Alanine Aminotransferase (ALT) (SGPT) >3 times the upper limit of normal
- •Received or are likely to receive an advanced therapy (e.g., mechanical circulatory support or lung or heart transplant) in the next 12 months
- •Subjects with congenital heart disease or mechanical/tissue right heart valve(s)
- •Subjects with known coagulation disorders
- •Subjects with a hypersensitivity or allergy to platelet aggregation inhibitors including aspirin, clopidogrel, prasugrel, and ticagrelor; or patients unable to take dual antiplatelet or anticoagulants for one- month post implant
- •Known history of life threatening allergy to contrast dye
- •Subjects who are pregnant or breastfeeding
- •Subjects who are unwilling or deemed by the Investigator to be unwilling to comply with the study protocol, or subjects with a history of non-compliance
- •Severe illness, other than heart disease, which would limit survival to <1 year
- •Subjects whose clinical condition, in the opinion of the Investigator, makes them an unsuitable candidate for the study
- •Subjects enrolled in another investigational trial with an active Treatment Arm
- •Subject who is in custody by order of an authority or a court of law
- •Unrepaired severe valvular disease
- •Subjects with an inferior vena cava (IVC) filter
研究组 & 干预措施
Cordella™ Pulmonary Artery Sensor System
Experimental
The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management
干预措施: Cordella™ Pulmonary Artery Sensor System (Device)
结局指标
主要结局
Safety: Freedom from Adverse Events
时间窗: 30 days
To evaluate the primary safety endpoint: Freedom from AEs associated with use of the CorPASS through 30 days post Cordella PA Sensor implant, the number of subjects with and without any Adverse Device Events will be summarized.
Accuracy of Cordella PA Sensor System pressure measurements, compared to standard-of-care fluid-filled catheter PA pressure measurements obtained by standard Right Heart Catheterization (RHC)
时间窗: 90 days
System accuracy will be compared to the accuracy of standard-of-care commercial products that use fluid-filled invasive catheters to measure PA pressure at 90 days post implant visit.
次要结局
- Device/system-related complications(30 days and 2 years)
- HF related hospitalizations, treatments in a hospital day-care setting, or urgent outpatient clinic visits.(90 days and 2 years)
- Frequency of Adverse Events(30 days and 2 years)
- Accuracy of Cordella PA Sensor pressure measurements(12 months)
- Quality of Life measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)(90 days and 2 years)
- Functional Status Change as measured by 6-Minute Walk Test(90 days and 2 years)
- Pressure sensor failure rate(30 days and 2 years)
- Heart Failure related medication changes(90 days and 2 years)
- Device Success(90 days)
- Change in Pulmonary Artery (PA) pressure(90 days and 2 years)
- Adherence to regular myCordella™ Peripherals measurements measured as a percentage of subjects who adhere to regular myCordella™ Peripherals measurements(90 days and 2 years)
- Functional Status Change as measured by New York Heart Association (NYHA) functional classification(90 days and 2 years)
- Accuracy using the Bland Altman Method(90 days)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
不适用
SIRONA Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT03375710Endotronix, Inc.15
进行中（未招募）
不适用
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04089059Endotronix, Inc.738
招募中
不适用
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLPrimary Central Nervous System LymphomaNCT06445257Huai'an First People's Hospital30
Unknown
不适用
Evaluation of Performance and Safety of Colonic Irrigation With the Colon Hydromat as a Non-oral Bowel Preparation for ColonoscopyColonic IrrigationNCT04684082Herrmann Apparatebau GmbH28
招募中
1 期
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant EpilepsyEpilepsyDrug Resistant EpilepsySeizures, FocalSeizureSeizure DisorderNCT06388707NaviFUS Corporation8